Gwark Sungchan, Kim Jisun, Chung Il Yong, Kim Hee Jeong, Ko Beom Seok, Lee Jong Won, Son Byung Ho, Ahn Sei Hyun, Lee Sae Byul
Department of Surgery, Ewha Womans University College of Medicine, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea.
Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Front Oncol. 2024 Jun 28;14:1392592. doi: 10.3389/fonc.2024.1392592. eCollection 2024.
Male breast cancer (MBC) is a rare condition, and recent research has underscored notable distinctions between MBC and breast cancer in women. This study aimed to assess and contrast the long-term survival outcomes and disease patterns of MBC patients with those of their female counterparts.
We analyzed data from 113,845 patients diagnosed with breast cancer who had undergone curative surgery from the Korean Breast Cancer Registry (KBCR) between January 1990 and August 2014 in Seoul, Korea. The five-year overall survival was analyzed according to clinicopathological characteristics.
Among 113,845 patients with breast cancer, 473 MBC cases were included. The median duration of follow-up was 72 months. The median age at diagnosis was 60 and 48 years for MBC and female breast cancer, respectively. Most male patients (92.6%) underwent total mastectomy, while 50.4% of female patients underwent breast-conserving surgery. Among MBC, 63.2% received chemotherapy, and 83.9% of hormone receptor-positive male patients received endocrine therapy. In survival analysis, MBC demonstrated distinct 5-year overall survival patterns compared with female breast cancer, according to age at diagnosis. In women with breast cancer, the younger age group (≤40 years) demonstrated worse 5-year overall survival than did the older age group (>40 years) (91.3% vs 92.7%, p <0.05). While in MBC, the younger age group (≤40 years) demonstrated better 5-year overall survival than did the older age group (>40 years) (97.4% vs 86.4%, p <0.05).
In conclusion within this extensive cohort, we have revealed unique survival patterns in MBC that diverge from those observed in women with breast cancer. This study enhances our comprehension of MBC prognosis and can potentially shed light on unresolved questions, paving the way for future research in the realm of MBC.
男性乳腺癌(MBC)是一种罕见疾病,近期研究强调了MBC与女性乳腺癌之间的显著差异。本研究旨在评估并对比MBC患者与女性乳腺癌患者的长期生存结局及疾病模式。
我们分析了1990年1月至2014年8月间在韩国首尔的韩国乳腺癌登记处(KBCR)接受根治性手术的113,845例乳腺癌患者的数据。根据临床病理特征分析了五年总生存率。
在113,845例乳腺癌患者中,纳入了473例MBC病例。中位随访时间为72个月。MBC和女性乳腺癌的诊断中位年龄分别为60岁和48岁。大多数男性患者(92.6%)接受了全乳切除术,而50.4%的女性患者接受了保乳手术。在MBC患者中,63.2%接受了化疗,83.9%的激素受体阳性男性患者接受了内分泌治疗。在生存分析中,根据诊断年龄,MBC与女性乳腺癌相比呈现出不同的五年总生存模式。在女性乳腺癌患者中,较年轻年龄组(≤40岁)的五年总生存率低于较年长年龄组(>40岁)(91.3%对92.7%,p<0.05)。而在MBC患者中,较年轻年龄组(≤40岁)的五年总生存率高于较年长年龄组(>40岁)(97.4%对86.4%,p<0.05)。
总之,在这个庞大的队列中,我们揭示了MBC独特的生存模式,与女性乳腺癌患者的模式不同。本研究增进了我们对MBC预后的理解,并可能为未解决的问题提供线索,为MBC领域的未来研究铺平道路。